Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide.
+ 1 more risk
Moderate growth potential with imperfect balance sheet.
Share Price & News
How has Catalent's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CTLT's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CTLT exceeded the US Pharmaceuticals industry which returned 10.6% over the past year.
Return vs Market: CTLT exceeded the US Market which returned 9.1% over the past year.
Price Volatility Vs. Market
How volatile is Catalent's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StAre Catalent's (NYSE:CTLT) Statutory Earnings A Good Guide To Its Underlying Profitability?
3 weeks ago | Simply Wall StWhat Is Catalent's (NYSE:CTLT) P/E Ratio After Its Share Price Rocketed?
1 month ago | Simply Wall StA Rising Share Price Has Us Looking Closely At Catalent, Inc.'s (NYSE:CTLT) P/E Ratio
Is Catalent undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CTLT ($77.73) is trading above our estimate of fair value ($31.16)
Significantly Below Fair Value: CTLT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CTLT is poor value based on its PE Ratio (109.5x) compared to the Pharmaceuticals industry average (16.6x).
PE vs Market: CTLT is poor value based on its PE Ratio (109.5x) compared to the US market (15.9x).
Price to Earnings Growth Ratio
PEG Ratio: CTLT is poor value based on its PEG Ratio (3.6x)
Price to Book Ratio
PB vs Industry: CTLT is overvalued based on its PB Ratio (5.5x) compared to the US Pharmaceuticals industry average (3.2x).
How is Catalent forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CTLT's forecast earnings growth (30.3% per year) is above the savings rate (2.2%).
Earnings vs Market: CTLT's earnings (30.3% per year) are forecast to grow faster than the US market (21.7% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CTLT's revenue (8.5% per year) is forecast to grow slower than the US market (8.8% per year).
High Growth Revenue: CTLT's revenue (8.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CTLT's Return on Equity is forecast to be low in 3 years time (13.7%).
How has Catalent performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CTLT has a large one-off loss of $58.7M impacting its March 31 2020 financial results.
Growing Profit Margin: CTLT's current net profit margins (3.6%) are lower than last year (6%).
Past Earnings Growth Analysis
Earnings Trend: CTLT's earnings have declined by -10.8% per year over the past 5 years.
Accelerating Growth: CTLT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CTLT had negative earnings growth (-29.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.5%).
Return on Equity
High ROE: CTLT's Return on Equity (4.9%) is considered low.
How is Catalent's financial position?
Financial Position Analysis
Short Term Liabilities: CTLT's short term assets ($1.7B) exceed its short term liabilities ($917.1M).
Long Term Liabilities: CTLT's short term assets ($1.7B) do not cover its long term liabilities ($3.4B).
Debt to Equity History and Analysis
Debt Level: CTLT's debt to equity ratio (109.6%) is considered high.
Reducing Debt: CTLT's debt to equity ratio has reduced from 382.6% to 109.6% over the past 5 years.
Debt Coverage: CTLT's debt is not well covered by operating cash flow (11.6%).
Interest Coverage: CTLT's interest payments on its debt are not well covered by EBIT (2.7x coverage).
What is Catalent's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CTLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CTLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTLT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTLT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTLT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Chiminski (55yo)
Mr. John R. Chiminski has been the Chief Executive Officer at Catalent, Inc. since March 2009 and has been its Chairman since October 25, 2016. He also served as President at Catalent, Inc. until February, ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD8.51M) is about average for companies of similar size in the US market ($USD11.65M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
|Chairman & CEO||11.17yrs||US$8.51m||0.14% $16.7m|
|President & COO||1.17yrs||US$1.88m||0.0085% $1.0m|
|Senior VP & CFO||2.17yrs||US$1.74m||0.030% $3.6m|
|Senior VP||no data||US$1.69m||0.041% $4.9m|
|President of Gene Therapy||1yr||US$4.54m||0.029% $3.5m|
|VP & Chief Scientific Officer||0.50yr||no data||no data|
|Vice President of Investor Relations||0.33yr||no data||no data|
|Senior Vice President of Strategy & Corporate Development||0.58yr||no data||0.011% $1.3m|
|Senior VP & Chief Human Resources Officer||0.83yr||no data||0.0072% $860.9k|
|President of Softgel & Oral Technologies||1.33yrs||no data||0.029% $3.5m|
Experienced Management: CTLT's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
|Chairman & CEO||11.17yrs||US$8.51m||0.14% $16.7m|
|Independent Director||4.5yrs||US$294.98k||0.027% $3.2m|
|Independent Director||6.33yrs||US$284.98k||0.0098% $1.2m|
|Independent Lead Director||3.58yrs||US$314.98k||0.016% $1.9m|
|Independent Director||5.08yrs||US$287.48k||0.030% $3.6m|
|Independent Director||4.83yrs||US$284.98k||0.015% $1.9m|
|Independent Director||2.17yrs||US$299.98k||0.012% $1.4m|
|Member of Advisory Board||4.75yrs||no data||no data|
|Member of Scientfic & Advisory Board||4.75yrs||no data||no data|
|Member of Advisory Board||4.75yrs||no data||no data|
Experienced Board: CTLT's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.3%.
Catalent, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Catalent, Inc.
- Ticker: CTLT
- Exchange: NYSE
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$12.040b
- Shares outstanding: 154.90m
- Website: https://www.catalent.com
Number of Employees
- Catalent, Inc.
- 14 Schoolhouse Road
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CTLT||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jul 2014|
|0C8||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2014|
|CTLT *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jul 2014|
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment engages in the drug substance development and manufacturing; drug product clinical and commercial manufacturing; and integrated clinical and commercial supply solutions for protein and gene therapy biologics and specialty small molecules through injection, inhalation, and ophthalmic routes. The Oral Drug Delivery segment formulates, develops, and manufactures technologies and related integrated solutions for a range of oral dose forms, including its proprietary fast-dissolve Zydis tablets and conventional tablets, capsules, and sachet products. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. It has an agreement with Cycle Pharmaceuticals Ltd. to develop formulations targeting rare disease patients; a collaboration with the Janssen Pharmaceutical Companies, as well as Ennaid Therapeutics; and a partnership with Arcturus Therapeutics Holdings Inc. to support the manufacture of LUNAR-COV19. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/30 06:49|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.